Moreover, we further immunostained tumor tissues with CD86 and CD206, and the results were fully consistent with our previous findings that treatment with NaHS led to a decrease in CD206 and an increase in CD86 in tumor tissues obtained from BC‐bearing mice (Figure 3G). This evidence concerns the gene MRC1 and breast cancer.